AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2025-06-19T03:31:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -6.71900M | 1.70M | 0.78M | -7.50300M | 5.07M |
| Minority interest | - | - | - | - | - |
| Net income | -6.12200M | 1.36M | 1.00M | -5.83800M | 3.99M |
| Selling general administrative | 6.41M | 5.64M | 6.12M | 5.93M | 6.42M |
| Selling and marketing expenses | 13.25M | 9.48M | 8.26M | 9.00M | 8.47M |
| Gross profit | 21.59M | 19.29M | 19.16M | 18.01M | 24.75M |
| Reconciled depreciation | 1.01M | 1.21M | 1.46M | 1.66M | 0.43M |
| Ebit | -2.97900M | 2.10M | -0.35100M | -1.08600M | 5.33M |
| Ebitda | -1.96600M | 2.61M | 1.11M | 0.58M | 5.88M |
| Depreciation and amortization | 1.01M | 0.51M | 1.46M | 1.66M | 0.55M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -3.01900M | 0.99M | 0.96M | -0.39800M | 5.33M |
| Other operating expenses | -7.35400M | 0.36M | -1.47800M | -8.03800M | 37.51M |
| Interest expense | 0.65M | 0.40M | 0.33M | 0.42M | 0.26M |
| Tax provision | -0.59700M | 0.34M | -0.22200M | -1.66500M | 1.07M |
| Interest income | 0.61M | 0.23M | 1.14M | 0.42M | 0.26M |
| Net interest income | -0.65200M | -0.40100M | -0.33000M | -0.42000M | -0.26100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.59700M | 0.34M | -0.22200M | -1.66500M | 1.08M |
| Total revenue | 42.41M | 37.76M | 35.74M | 35.07M | 41.51M |
| Total operating expenses | 26.14M | 19.69M | 18.76M | 18.77M | 20.76M |
| Cost of revenue | 20.82M | 18.46M | 16.58M | 17.06M | 16.75M |
| Total other income expense net | -2.53300M | 1.99M | 0.71M | -6.32700M | -0.26100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -6.12200M | 1.36M | 1.00M | -5.83800M | 4.02M |
| Net income applicable to common shares | -6.12200M | 1.36M | 1.00M | -5.83800M | 4.02M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 40.15M | 41.18M | 41.49M | 38.55M | 35.53M |
| Intangible assets | - | 6.24M | 6.45M | 4.08M | 2.78M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.71M | 2.43M | 2.35M | 2.47M | 1.05M |
| Total liab | 22.13M | 22.89M | 17.90M | 16.39M | 13.73M |
| Total stockholder equity | 18.02M | 18.29M | 23.59M | 22.16M | 21.79M |
| Deferred long term liab | - | 6.24M | 6.45M | 4.08M | 2.78M |
| Other current liab | 4.46M | 4.26M | 3.51M | 3.15M | 2.93M |
| Common stock | 35.65M | 35.65M | 35.65M | 35.65M | 35.65M |
| Capital stock | - | 35.65M | 35.65M | 35.65M | 35.65M |
| Retained earnings | -17.47300M | -17.79100M | -11.66900M | -13.02600M | -13.90200M |
| Other liab | - | 0.14M | 0.20M | 0.29M | 0.45M |
| Good will | - | - | - | - | - |
| Other assets | - | 1.10M | 6.95M | 4.90M | 3.56M |
| Cash | 1.89M | 3.80M | 7.08M | 6.77M | 6.41M |
| Cash and equivalents | - | - | 7.08M | - | - |
| Total current liabilities | 21.22M | 21.19M | 17.32M | 15.35M | 12.44M |
| Current deferred revenue | 1.34M | 2.69M | 1.92M | 1.75M | 1.72M |
| Net debt | 6.68M | 5.67M | -0.74700M | -0.95000M | -1.61300M |
| Short term debt | 7.72M | 7.91M | 5.95M | 5.07M | 3.95M |
| Short long term debt | - | 7.22M | 5.80M | 4.41M | 3.05M |
| Short long term debt total | 8.56M | 9.47M | 6.33M | 5.82M | 4.80M |
| Other stockholder equity | -0.16500M | -17.86300M | -23.98500M | -22.62800M | -21.63000M |
| Property plant equipment | - | 3.62M | 1.21M | 1.71M | 3.08M |
| Total current assets | 25.95M | 29.52M | 33.33M | 31.93M | 28.89M |
| Long term investments | - | 0.70M | - | - | - |
| Net tangible assets | - | 18.29M | 23.59M | 22.16M | 21.79M |
| Short term investments | - | - | - | - | - |
| Net receivables | 10.45M | 12.53M | 14.12M | 13.01M | 12.60M |
| Long term debt | - | 0.20M | 0.38M | 0.59M | 0.01M |
| Inventory | 12.91M | 10.69M | 9.71M | 9.68M | 8.83M |
| Accounts payable | 7.70M | 6.33M | 5.94M | 5.38M | 3.83M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | 0.43M | -0.39400M | -0.47300M | 0.04M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 35.65M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 10.16M | - | -1.21300M | -1.71100M | -3.08300M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 14.20M | 11.66M | 8.16M | 6.61M | 6.64M |
| Capital lease obligations | - | 2.04M | 0.15M | 0.82M | 1.74M |
| Long term debt total | - | 1.56M | 0.38M | 0.75M | 0.85M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -4.40800M | -2.95900M | -1.84300M | -4.23300M | -4.28600M |
| Change to liabilities | 0.49M | 0.92M | 1.40M | -1.68800M | 0.22M |
| Total cashflows from investing activities | -4.40800M | -2.95900M | -1.55400M | -4.23300M | -4.28600M |
| Net borrowings | -1.00500M | 1.28M | -0.17900M | 0.45M | 0.15M |
| Total cash from financing activities | -1.00500M | 1.28M | -0.17900M | 0.45M | 0.15M |
| Change to operating activities | 0.68M | 0.52M | -1.11800M | 0.79M | 0.18M |
| Net income | -6.12200M | 1.36M | 1.00M | -5.83800M | 3.99M |
| Change in cash | -4.99400M | 1.94M | -0.87300M | 1.64M | 1.17M |
| Begin period cash flow | 7.29M | 5.14M | 6.01M | 4.37M | 3.20M |
| End period cash flow | 2.30M | 7.08M | 5.14M | 6.01M | 4.37M |
| Total cash from operating activities | 0.05M | 3.29M | 1.32M | 5.38M | 5.14M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 0.98M | 1.13M | 1.37M | 1.48M | 0.55M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.98100M | -0.03000M | -0.84700M | -1.03300M | -0.23700M |
| Change to account receivables | 1.51M | -0.98700M | -0.41500M | 3.38M | 0.47M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -0.14500M | 3.83M | -0.12100M | 2.03M | 0.88M |
| Change to netincome | 3.37M | 0.60M | -0.04100M | 8.01M | -0.00200M |
| Capital expenditures | 4.41M | 2.96M | 1.84M | 4.23M | 4.29M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.53M | -1.01700M | -1.26200M | 2.35M | 0.40M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | 4.66M | 1.81M | 0.22M | 7.39M | -4.44400M |
| Free cash flow | -4.35900M | 0.33M | -0.51900M | 1.15M | 0.85M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CMP Compumedics Ltd |
-0.005 1.89% | 0.26 | - | - | 1.12 | 2.43 | 1.29 | 54.01 |
| COH Cochlear Ltd |
4.65 1.64% | 288.43 | 47.77 | 38.76 | 7.65 | 9.44 | 7.58 | 29.28 |
| PNV Polynovo Ltd |
-0.005 0.41% | 1.21 | 126.50 | 147.06 | 7.56 | 11.58 | 7.45 | 93.59 |
| IMR Imricor Medical Systems Inc |
0.01 0.66% | 1.53 | - | - | 564.46 | 3.97 | 374.91 | -2.6027 |
| EBR Ebr Systems Inc CDR |
-0.09 7.69% | 1.08 | - | - | - | 19.90 | -3.6785 |
Compumedics Limited engages in the research, development, manufacture, and distribution of medical equipment and related technologies in Australia, the Asia Pacific, the United States, and Europe. It provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients' physiological data; Somté PSG; Okti; Grael PSG; Grael 4K PSG; Falcon PSG; Falcon HST; Somté, an investigative tool; Siesta 802; and Somté PSG. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, an portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that offers integrated hardware and software solutions for sleep and neurology clinics; CURRY, a signal processing and soutce localization multi-modal neuroimaging suite; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, TCM5 FLEX transcutaneous monitors, Grael DC, and persyst software products. Further, the company offers magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; and consumables and supplies for diagnostic and research solutions. Additionally, the company provides doppler diagnostics; Nuevo LTM EEG; Orion LifeSpan MEG; and quick-cap EEG electrode arrays. Compumedics Limited was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited is a subsidiary of D & DJ Burton Holdings Pty Ltd.
30-40 Flockhart Street, Abbotsford, VIC, Australia, 3067
| Name | Title | Year Born |
|---|---|---|
| Dr. David Burton Ph.D. | Founder, Exec. Chairman, CEO & Member of Medical Advisory Board | 1959 |
| Mr. David Francis Lawson | CFO, Company Sec. & Exec. Director | 1965 |
| Mr. Warwick Freeman | Chief Technology Officer | NA |
| Mr. Christoph Witte | Gen. Managing of Director DWL Compumedics Germany GmbH | NA |
| Dr. Kerry Trent Hubick | Legal Counsel and Trademark, Patent & Gen. Legal Attorney | NA |
| Dr. Curtis Ponton | Chief Scientist of Neuroscan & VP | NA |
| Mr. Paul Spooner | Bus. Director of EMEA | NA |
| Dr. David Burton Ph.D. | Founder, Executive Chairman, CEO & Member of Medical Advisory Board | 1959 |
| Mr. David Francis Lawson | CFO, Company Secretary & Executive Director | 1965 |
| Dr. Kerry Trent Hubick | Legal Counsel and Trademark, Patent & General Legal Attorney | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...